The Prevalence of Hpv and Non-Hpv Stis Among Iranian Women and Assessment of the Hpv/Non-Hpv Stis Co-Infection on Cervical Cell Changes Publisher



Pouryasin M¹ ; Mousavi AS^{2, 3, 4} ; Pakravesh J⁵ ; Kamel DZ¹ ; Nooriardabili S⁶ ; Khodadad S^{3, 7} ; Aminimoghaddam S⁸ ; Ghazimoghadam M⁹ ; Farbod Y⁸ ; Pouryasin A¹ Show Affiliations
Source: Journal of Obstetrics# Gynecology and Cancer Research Published:2022

Abstract

Background & Objective: Persistent infection with some types of Human papillomavirus (HPV), which are high-risk genotypes, can lead the patients toward cervical cancer and, finally, death. Recent studies showed HPV co-infection with non-HPV sexually transmitted infections (non-HPV STIs) could increase the persistency rate of HPV infections. This study aimed to estimate the prevalence of STIs and assess the association of HPV/non-HPV STIs co-infection on cervical cell changes based on cytological findings. Materials & Methods: In this cross-sectional study, in addition to the routine cervical screening, including HPV testing and cytological assessment, non-HPV STI testing was performed on 1065 Iranian women. To assess the HPV and non-HPV STIs, commercial kits were used. Results: 964 (90.5%) women had normal cytology (NILM) results. The overall prevalence of HPV and non-HPV STIs were 39.1% and 68.5%, respectively. HPV-53 (6.5%),-16 (6.1%) and-31 (5.5%) were found as the most prevalent genotypes. Ureaplasma Parvum (UP) (42.7%), Group B Streptococcus (GBS) (23.7%), Candida Species (CS) (23.6%), Ureaplasma Urealyticum (UU) (9.6%), and Mycoplasma Hominis (MH) (7.1%) were found as the most prevalent non-HPV STIs. The co-infection of HPV with GBS played an important role in developing the cervical lesion (P<0.05). Conclusion: In the present study, the STIs, including HPV, UP, GBS, CS, UU, and MH, were prevalent among the study participant, and it was found that the HPV/GBS co-infection played a significant role in the development of LSIL or worse cytological grades. To clarify this issue, further studies will be conducted. © 2022, Farname Inc. All rights reserved.